Latest:
Understanding the Implications of Mandatory Vendor Imposition in Oncology
The rising costs of healthcare have caused payers to analyze spending and take measures to contain costs.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Michael A. Postow, MD
Michael A. Postow, MD, is chief of the Melanoma Service and co-director of the Melanoma Disease Management Team at Memorial Sloan Kettering Cancer Center in New York, New York.
Latest:
Key Areas of Future Research in Advanced Melanoma
Michael A. Postow, MD, and Chenyang Zhan, MD, PhD, discuss ongoing research to watch in advanced melanoma.
Michael A. Rodriguez, MD, MPH
Latest:
Cervical Cancer Screening Overuse and Underuse: Patient and Physician Factors
For a decade, US medical professional organizations and the US Preventive Services Task Force have suggested that low-risk women (history of multiple normal Papanicolaou [pap] tests, age over 30 years) receive cervical cancer screening every 3 years as part of routine preventive services.
Michael A. Samuels, MD
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Michael B. Atkins, MD
Latest:
Rapid Readouts: Results of Phase 3 DREAMseq Trial in Advanced Melanoma
Michael Atkins, MD, shares data presented at the 2021 American Society of Clinical Oncology Plenary Series regarding results from the phase 3 ECOG-ACRIN EA6134 trial, DREAMseq, evaluating the use of up-front dual immunotherapy in patients with BRAF V600–mutant advanced melanoma.
Michael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center
Latest:
Initial Efficacy and Safety of RP1 + Nivolumab in Patients With Anti–PD-1–Failed Melanoma From the Ongoing Phase 1/2 IGNYTE Study
Expert Michael Atkins, MD, reviews data from the ongoing IGNYTE study utilizing RP1 in combination with nivolumab in relapsed/refractory melanoma.
Michael Birrer, MD, PhD
Latest:
Future of Gynecologic Oncology: Integrating Antibody-Drug Conjugates and Novel Combinations Into the IO Sequencing Paradigm for Advanced EC
Panelists discuss how future therapies, such as antibody-drug conjugates (ADCs) and novel combination therapies, could enhance immuno-oncology (IO) sequencing by offering more targeted options for patients who have progressed on initial IO therapies, while addressing resistance mechanisms and improving overall treatment outcomes.